What is pathophysiology of Alzheimer?

Lalela leli khasi

Iyini i-pathophysiology ye-alzheimer's?

I-pathophysiology yesifo sika-Alzheimer (AD) iyinqubo eyinkimbinkimbi ehilela ukuqoqwa kwamaprotheni angavamile, ukuvuvukala, nokungasebenzi kahle kwezinzwa.

Izimpawu ezimbili eziyinhloko ze-AD ukuba khona kwama-plaque e-amyloid-beta (Aβ) nama-neurofibrillary tangles (NFTs) ebuchosheni.

Ama-amyloid-beta plaques akhiwa lapho izingcezu ze-amyloid precursor protein (APP) zihlukaniswa ama-enzyme ukuze kwakheke ama-Aβ peptides.

Lawa ma-peptide ahlangana futhi akha ama-fibrils angaxazululeki aqoqana ngaphandle kwama-neuron, aphazamisa ukuxhumana kwamangqamuzana namangqamuzana futhi aholele ekufeni kwama-neuron.

Ukuqoqwa kwama-Aβ plaques kucatshangwa ukuthi kungenye yezenzakalo zokuqala ekuthuthukiseni i-AD, futhi kukholakala ukuthi kunomthelela enqubweni ye-neurodegenerative.

Ama-neurofibrillary tangles akhiwa lapho i-protein tau i-hyperphosphorylated futhi yakha imicu engajwayelekile ngaphakathi kwama-neuron.

Lezi zinhlayiya ziphazamisa ukusebenza okujwayelekile kwama-microtubule, abalulekile ekuthuthweni kwezakhi nezinye izinto ngaphakathi kwe-neuron.

Lezi zingxabano ekugcineni ziholela ekufeni kwamangqamuzana ezinzwa athintekile.

Ukuvuvukala nakho kudlala indima ku-pathophysiology ye-AD.

Isimiso somzimba sokuzivikela ezifweni sisabela ekuqongeleleni kwama-Aβ plaques nama-NFTs ngokukhulula ama-cytokine athuthukisa ukuvuvukala, angandisa umonakalo kuma-neuron.

Ngaphezu kwalokho, kunobufakazi bokuthi ukucindezeleka kwe-oxidative, ukungasebenzi kahle kwe-mitochondrial, nokuphazamiseka kwe-glucose metabolism kunomthelela ku-pathophysiology ye-AD.

Lezi zici zingaholela ekungasebenzi kahle kwamangqamuzana ezinzwa nasekufeni, kuqhubeke kubhebhethekise inqubo yesifo.

Sekukonke, i-pathophysiology ye-AD iwukuxhumana okuyinkimbinkimbi kwezinto eziningi ekugcineni okuholela ekwehleni okuqhubekayo komsebenzi wokuqonda nokulahleka kwememori okuchaza lesi sifo.

Izikhombo

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nemeroff CB: The preeminent role of neuropeptide systems in the early pathophysiology of Alzheimer disease: up with corticotropin-releasing factor, down with acetylcholine. Arch Gen Psychiatry. 1999, 56 (11): 991-2.

Skoog I, Kalaria RN, Breteler MM: Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord. , 13 Suppl 3 (): S106-14.

Proft J, Weiss N: Jekyll and Hide: The two faces of amyloid β. Commun Integr Biol. 2012, 5 (5): 405-7.

Whitehouse PJ, Hedreen JC, White CL, Price DL: Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol. 1983, 13 (3): 243-8.

Casadesus G, Moreira PI, Nunomura A, Siedlak SL, Bligh-Glover W, Balraj E, Petot G, Smith MA, Perry G: Indices of metabolic dysfunction and oxidative stress. Neurochem Res. , 32 (4-5): 717-22.

Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, Duro G, Lio D, Matranga D, Pellicanò M, Rizzo C, Scapagnini G, Vasto S: Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res. , 13 (2-3): 301-13.

Raskind MA, Peskind ER: Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer Dis Assoc Disord. 1994, 8 Suppl 3 (): 54-60.

Schindler SE, McConathy J, Ances BM, Diamond MI: Advances in diagnostic testing for Alzheimer disease. Mo Med. , 110 (5): 401-5.

Singh VK: Immune-activation model in Alzheimer disease. Mol Chem Neuropathol. , 28 (1-3): 105-11.

Ukuzikhulula: kwezokwelapha

Le webhusayithi inikezwa ngezinjongo zemfundo nezokwaziswa kuphela futhi ayifaki ukunikeza izeluleko zezokwelapha noma izinsizakalo zobungcweti.

Imininingwane enikeziwe akufanele isetshenziselwe ukuxilonga noma ukwelapha inkinga noma isifo, futhi labo abafuna iseluleko somuntu siqu sezokwelapha kufanele babonane nodokotela onelayisense.

Sicela uqaphele ukuthi inethiwekhi ye-neural ekhiqiza izimpendulo zemibuzo, ayinembile ngokukhethekile uma kuziwa kokuqukethwe kwezinombolo. Ngokwesibonelo, inani labantu abanesifo esithile.

Ngaso sonke isikhathi funa iseluleko sikadokotela wakho noma omunye umhlinzeki wezempilo ofanelekayo mayelana nesimo sezokwelapha. Ungalokothi ungayinaki iseluleko sezokwelapha sobungcweti noma ubambezele ukusifuna ngenxa yento oyifundile kule webhusayithi. Uma ucabanga ukuthi ungase ube nesimo esiphuthumayo sezokwelapha, shayela i-911 noma uye egumbini lezimo eziphuthumayo eliseduze ngokushesha. Ayikho ubudlelwano bokuthi udokotela-isiguli obakhiwe yile webhusayithi noma ukusetshenziswa kwayo. I-BioMedLib noma abasebenzi bayo, noma noma yimuphi umnikeli wale webhusayithi, akenzi noma yimiphi imibono, ecacile noma ecacile, mayelana nolwazi olunikezwe lapha noma ukusetshenziswa kwayo.

Ukuzikhulula: amalungelo obunikazi

I-Digital Millennium Copyright Act ka-1998, i-17 U.S.C. § 512 (i- DMCA) inikeza indlela yokuphendula kubanikazi bamalungelo obunikazi abakholelwa ukuthi okokusebenza okubonakala kwi-Internet kwephula amalungelo abo ngaphansi komthetho we-copyright wase-US.

Uma ukholelwa ngobuqotho ukuthi noma yikuphi okuqukethwe noma okokusebenza okwenziwe kutholakale maqondana newebhusayithi yethu noma izinsizakalo kwephula ilungelo lakho lobunikazi, wena (noma umenzeli wakho) ungasithumela isaziso esicela ukuthi okuqukethwe noma okokusebenza kususwe, noma ukufinyelela kukho kuvinjelwe.

Izaziso kufanele zithunyelwe ngokubhala nge-imeyili (bheka isigaba esithi "Contact" ukuze uthole ikheli le-imeyili).

I-DMCA idinga ukuthi isaziso sakho sokwephulwa kwamalungelo obunikazi kubandakanye imininingwane elandelayo: (1) incazelo yomsebenzi onamalungelo obunikazi oyisihloko sokwephulwa okusolwa; (2) incazelo yokuqukethwe okusolwa ukwephula amalungelo obunikazi nolwazi olwanele ukusivumela ukuthi sithole okuqukethwe; (3) imininingwane yokuxhumana nawe, kufaka phakathi ikheli lakho, inombolo yocingo nekheli le-imeyili; (4) isitatimende sakho sokuthi unokholo oluhle lokuthi okuqukethwe ngendlela ekhonjiwe ngayo akugunyaziwe ngumnikazi wamalungelo obunikazi, noma umenzeli wakhe, noma ngokusebenza kwanoma imuphi umthetho;

(5) isitatimende sakho, esisayinwe ngaphansi kwesijeziso sokufakaza amanga, sokuthi ukwaziswa okusesazisweni kunembile nokuthi unegunya lokuphoqelela amalungelo obunikazi okuthiwa aphuliwe;

futhi (6) isignesha ebonakalayo noma ye-elekthronikhi yomnikazi we-copyright noma umuntu ogunyaziwe ukuba asebenze egameni lomnikazi we-copyright.

Ukwehluleka ukufaka yonke imininingwane engenhla kungaholela ekubambezelweni kokucutshungulwa kwesikhalazo sakho.

Othintana naye

Sicela usithumelele i-imeyili nganoma yimiphi imibuzo / iziphakamiso.

What is pathophysiology of alzheimer?

The pathophysiology of Alzheimer's disease (AD) is a complex process that involves the accumulation of abnormal proteins, inflammation, and neuronal dysfunction.

The two main hallmarks of AD are the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain.

Amyloid-beta plaques are formed when fragments of the amyloid precursor protein (APP) are cleaved by enzymes to form Aβ peptides.

These peptides aggregate and form insoluble fibrils that accumulate outside neurons, disrupting cell-to-cell communication and leading to neuronal death.

The accumulation of Aβ plaques is thought to be one of the earliest events in the development of AD, and it is believed to contribute to the neurodegenerative process.

Neurofibrillary tangles are formed when the protein tau becomes hyperphosphorylated and forms abnormal filaments inside neurons.

These tangles disrupt the normal functioning of the microtubules, which are essential for the transport of nutrients and other materials within the neuron.

The tangles eventually lead to the death of the affected neurons.

Inflammation also plays a role in the pathophysiology of AD.

The immune system responds to the accumulation of Aβ plaques and NFTs by releasing pro-inflammatory cytokines, which can exacerbate the damage to neurons.

Additionally, there is evidence that oxidative stress, mitochondrial dysfunction, and impaired glucose metabolism contribute to the pathophysiology of AD.

These factors can lead to neuronal dysfunction and death, further exacerbating the disease process.

Overall, the pathophysiology of AD is a complex interplay of multiple factors that ultimately lead to the progressive decline in cognitive function and memory loss that characterizes the disease.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.